tert-butyl (5-acetyl-4-methylthiazol-2-yl)carbamate

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: tert-butyl (5-acetyl-4-methylthiazol-2-yl)carbamate
• 英文别名: Tert-butyl N-(5-acetyl-4-methyl-1,3-thiazol-2-YL)carbamate；tert-butyl N-(5-acetyl-4-methyl-1,3-thiazol-2-yl)carbamate
• 化学式: C₁₁H₁₆N₂O₃S
• 分子量: 256.326
• InChiKey: GNMBRHLFQLYQLV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  17
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.55
• 拓扑面积：
  96.5
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  tert-butyl (5-acetyl-4-methylthiazol-2-yl)carbamate 在 水 、 一水合肼 、 N,N'-羰基二咪唑 、 三氟乙酸 、 sodium hydroxide 、 lithium hexamethyldisilazane 作用下， 以 四氢呋喃 、 乙醇 、 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 80.25h， 生成 5-(2-benzamido-4-methyl-1,3-thiazol-5-yl)-1H-pyrazole-3-carboxylic acid
  参考文献：
  名称：

  一种酯基吡唑联噻唑胺化合物及其制备方法和应用

  摘要：

  本发明公开了一种酯基吡唑联噻唑胺化合物及其制备方法和应用，其结构通式为：。该化合物是一种双五元氮杂环双官能团化合物，便于实现噻唑胺和吡唑的高通量合成和多样化衍生，可广泛应用于噻唑联吡唑类药物研发和生产中。

  公开号：

  CN111606902A
• 作为产物：
  描述：

  5-乙酰基-2-氨基-4-甲基噻唑 、 二碳酸二叔丁酯 在 三乙胺 作用下， 以 四氢呋喃 为溶剂， 以89.2 %的产率得到tert-butyl (5-acetyl-4-methylthiazol-2-yl)carbamate
  参考文献：
  名称：

  [EN] COMPOUNDS AS ANTICANCER AGENTS
  [FR] COMPOSÉS EN TANT QU'AGENTS ANTICANCÉREUX

  摘要：

  Disclosed are the compounds of formula I, their use as inhibitors of pan KRAS :: SOS1, their pharmaceutical compositions and their use as medicaments uses, especially as agents for the treatment of oncological diseases including cancer.

  公开号：

  WO2022258057A1

文献信息

• Efficient synthesis and cell migration inhibitory effect of substituted benzamidothiazolylpyrazole-capped AWD*I-NH2
  作者：Mian Yang、Jun Chen、Wancai Peng、Qiqi Li、Hui Shao、Guanping Tang、Tong-Cun Zhang、Yoshikazhu Takada、Long Ye、Xing-Hua Liao

  DOI：10.1016/j.bmcl.2019.126914

  日期：2020.2

  Substituted (2-benzamidothiazol-5-yl)pyrazole-capped AWD*I-NH2 were synthesized and their antimigration activity was studied. The improved efficiency and scalability of the analog synthesis was achieved via a late-stage diversification of the benzoyl group and a convergent route in which the bisazole capping agents and off-resin peptide AWD*I-NH2 were prepared in parallel and coupled together in solution at the last step. Bioassay results indicate that all the peptidomimetics can significantly inhibit the migration of breast cancer cells MDA-MB-231 but possess no apparent cytotoxicity. In general, the antimigration potency of the peptidomimetics is correlated to the electron-withdrawing capacity of the substituents on the terminal phenyl ring. The inhibitory effect shows dose-dependent and holds also against lung and cervical cancer cells. The level of f-actin was reduced dramatically in cells treated with the inhibitor, suggesting that the migration inhibitory effect is related to the disruption of cell locomotive protrusions.